Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase

- Spelman, Tim, Eichau, Sara, Grammond, Pierre, Lechner-Scott, Jeanette, Gray, Orla, Amato, Maria Pia, Laureys, Guy, Shaygannejad, Vahid, Hyde, Robert, Wang, Haijue, Bozin, Ivan, Belviso, Nicholas, Alroughani, Raed, Quan, Chao, Zeng, Feng, van der Walt, Anneke, Butzkueven, Helmut, MSBase Study Group,, Ozakbas, Serkan, Khoury, Samia J, Patti, Francesco, Havrdova, Eva Kubala, Boz, Cavit, Terzi, Murat, Kuhle, Jens

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

- Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Morgado, Yolanda Blanco, Spitaleri, Daniele L. A., Pesch, Vincent Van, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, Abdullah, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, MSBase Study Group,, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Der Walt, Anneke Van, Yamout, Bassem, Lechner-Scott, Jeannette

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

- Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Blanco Morgado, Yolanda, Spitaleri, Daniele L. A., van Pesch, Vincent, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, A, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Van Der Walt, Anneke, Yamout, Bassem, Lechner-Scott, Jeannette

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation

- Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

- Roos, Izanne, Hughes, Stella, van der Walt, Anneke, Butzkueven, Helmut, Lechner-Scott, Jeannette, Kuhle, Jens, Terzi, Murat, Laureys, Guy, Van Hijfte, Liesbeth, John, Nevin, Grammond, Pierre, Grand'Maison, Francois, McDonnell, Gavin, Soysal, Aysun, Jensen, AV, Rasmussen, PV, Svendsen, KB, Barzinji, I, Nielsen, HH, Sejbæk, T, Prakash, S, Stilund, MLM, Weglewski, A, Malpas, Charles B., Issa, NM, Kant, M, Sellebjerg, F, Gray, O, Magyari, M, Kalincik, T, MSBase Study GroupDanish MS Registry Study Group,, Sharmin, Sifat, Boz, Cavit, Alroughani, Raed, Ozakbas, Serkan, Buzzard, Katherine, Skibina, Olga

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

- Zhu, Chao, Zhou, Zhen, Roos, Izanne, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

- Zhong, Michael, van der Walt, Anneke, Macdonell, Richard, Prevost, Julie, Kuhle, Jens, Laureys, Guy, Van Hijfte, Liesbeth, Alroughani, Raed, Kermode, Allan G., Butler, Ernest, Barnett, Michael, Eichau, Sara, Stankovich, Jim, van Pesch, V, Grammond, P, McCombe, P, Karabudak, R, Duquette, P, Girard, M, Taylor, B, Yeh, W, Monif, M, Gresle, M, Kalincik, Tomas, Butzkueven, H, Jokubaitis, VG, Buzzard, Katherine, Skibina, Olga, Boz, Cavit, Hodgkinson, Suzanne, Slee, Mark, Lechner-Scott, Jeanette

Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

- De Brouwer, Edward, Becker, Thijs, Kappos, Ludwig, Sola, Patrizia, Cartechini, Elisabetta, Lechner-Scott, Jeannette, Alroughani, Raed, Gerlach, Oliver, Kalincik, Tomas, Granella, Franco, Grand'Maison, Francois, Bergamaschi, Roberto, Moreau, Yves, José Sá, M, Van Wijmeersch, B, Soysal, A, Sanchez-Menoyo, JL, Solaro, C, Boz, C, Iuliano, G, Buzzard, K, Aguera-Morales, E, Terzi, M, Havrdova, Eva Kubala, Trivio, TC, Spitaleri, D, Van Pesch, V, Shaygannejad, V, Moore, F, Oreja-Guevara, C, Maimone, D, Gouider, R, Csepany, T, Ramo-Tello, C, Trojano, Maria, Peeters, L, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Grammond, Pierre, Kuhle, Jens

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

- Kalincik, Tomas, Kubala Havrdova, Eva, Ozakbas, Serkan, Kappos, Ludwig, Kuhle, Jens, Terzi, Murat, Lechner-Scott, Jeanette, Boz, Cavit, Grand'maison, Francois, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Horakova, Dana, Granella, Franco, Trojano, M, Bergamaschi, R, Pucci, E, Turkoglu, R, McCombe, PA, Pesch, VV, Van Wijmeersch, B, Solaro, C, Ramo-Tello, C, Izquierdo, Guillermo, Slee, M, Alroughani, R, Yamout, B, Shaygannejad, V, Spitaleri, D, Sánchez-Menoyo, JL, Ampapa, R, Hodgkinson, S, Karabudak, R, Butler, E, Prat, Alexandre, Vucic, S, Jokubaitis, V, Spelman, T, Butzkueven, H, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Onofrj, Marco, Lugaresi, Alessandra